TEL AVIV, Israel--(BUSINESS WIRE)--Orgenesis Inc., (OTCBB: ORGS) (the “Company”) announced today that pursuant to a licensing agreement dated February 2, 2012 with Tel Hashomer - Medical Research, Infrastructure and Services Ltd. (“Tel Hashomer” or “THM), the Company has an exclusive license to develop and commercialize THM’s rights in functional autologous insulin producing cells (AIPC) regeneration technology.
